Odonate Therapeutics, Inc.
ODTC · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | -$0 | -$0 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $36 | $117 |
| G&A Expenses | $0 | $0 | $0 | $10 |
| SG&A Expenses | $1 | $4 | $9 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $1 | $4 | $46 | $127 |
| Operating Income | -$1 | -$4 | -$47 | -$127 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $10 | $14 | -$21 | $1 |
| Pre-Tax Income | $9 | $10 | -$68 | -$126 |
| Tax Expense | $2 | -$33 | $0 | $0 |
| Net Income | $7 | $43 | -$68 | -$126 |
| % Margin | – | – | – | – |
| EPS | 6.818 | 39,375.729 | -48,889.111 | -102,517.747 |
| % Growth | -100% | 180.5% | 52.3% | – |
| EPS Diluted | 6.805 | 39,311.069 | -48,889.111 | -102,517.747 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | $9 | $10 | -$67 | -$125 |
| % Margin | – | – | – | – |